Repligen Corporation (RGEN)
| Bid | 126.31 |
| Market Cap | 7.12B |
| Revenue (ttm) | 627.84M |
| Net Income (ttm) | -29.11M |
| EPS (ttm) | -0.45 |
| PE Ratio (ttm) | -281.62 |
| Forward PE | 98.54 |
| Analyst | Buy |
| Ask | 126.85 |
| Volume | 254,597 |
| Avg. Volume (20D) | 753,972 |
| Open | 124.27 |
| Previous Close | 122.86 |
| Day's Range | 123.50 - 128.28 |
| 52-Week Range | 102.97 - 182.52 |
| Beta | 1.27 |
About RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used i...
Analyst Forecast
According to 12 analyst ratings, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is $180, which is an increase of 42.03% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
Repligen Purchases Bioprocessing Analytics Portfolio from 908 DevicesWALTHAM, Mass., & BOSTON--(BUSINESS WIRE)--Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer i...
